Jaguar Health (JAGX) Stock Price, News & Analysis

-0.02 (-12.62%)
(As of 09:09 AM ET)
Today's Range
50-Day Range
52-Week Range
7.86 million shs
Average Volume
50.87 million shs
Market Capitalization
$43.42 million
P/E Ratio
Dividend Yield
Price Target
JAGX stock logo

About Jaguar Health Stock (NASDAQ:JAGX)

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.

JAGX Stock Price History

JAGX Stock News Headlines

Jaguar Health (NASDAQ:JAGX) Now Covered by
Why Jaguar Health Stock Is Up Today
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Gold Moves Higher; Morgan Stanley Earnings Top Views
Why Is Jaguar Health (JAGX) Stock Up 44% Today?
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
What Wall Street expects from Jaguar Health's earnings
Jaguar Health, Inc.
Capricor Therapeutics, Inc. (4LN2.F)
Jaguar Health Inc
Jaguar Health, Inc. (JAGX)
See More Headlines
Receive JAGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jaguar Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$9.76 million
Book Value
$0.07 per share


Free Float
Market Cap
$49.69 million
No Data
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Ms. Lisa A. Conte (Age 65)
    Founder, CEO, President & Director
    Comp: $771.4k
  • Dr. Pravin R. Chaturvedi Ph.D. (Age 61)
    Chief Scientific Officer & Chair of Scientific Advisory Board
    Comp: $539.04k
  • Mr. Jonathan S. Wolin CPA (Age 61)
    J.D., M.B.A., Chief of Staff, Chief Compliance Officer & General Counsel
    Comp: $520.29k
  • Mr. Ian H. Wendt M.B.A. (Age 56)
    Chief Commercial Officer
    Comp: $441.31k
  • Dr. Steven R. King Ph.D. (Age 66)
    Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Secretary
    Comp: $477.66k
  • Ms. Carol R. Lizak M.B.A. (Age 60)
    Chief Financial Officer
  • Mr. Peter Hodge
    Senior Director of Investor Relations, Business Development & Special Events
  • Dr. Karen J. Brunke Ph.D. (Age 71)
    Executive VP of Corporate & Business Development
  • Mr. David Sesin
    Chief Manufacturing Officer
  • Dr. Massimo Radaelli M.B.A. (Age 66)
    Ph.D., President of Jaguar International

JAGX Stock Analysis - Frequently Asked Questions

How have JAGX shares performed in 2024?

Jaguar Health's stock was trading at $0.1514 at the beginning of 2024. Since then, JAGX stock has increased by 18.8% and is now trading at $0.1799.
View the best growth stocks for 2024 here

Are investors shorting Jaguar Health?

Jaguar Health saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 19,710,000 shares, an increase of 164.9% from the March 15th total of 7,440,000 shares. Based on an average daily trading volume, of 40,390,000 shares, the days-to-cover ratio is presently 0.5 days.
View Jaguar Health's Short Interest

When is Jaguar Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our JAGX earnings forecast

How were Jaguar Health's earnings last quarter?

Jaguar Health, Inc. (NASDAQ:JAGX) released its quarterly earnings data on Wednesday, November, 17th. The biotechnology company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.09. The biotechnology company had revenue of $0.63 million for the quarter. Jaguar Health had a negative trailing twelve-month return on equity of 837.11% and a negative net margin of 423.11%. During the same period in the previous year, the firm earned ($0.63) EPS.

When did Jaguar Health's stock split?

Jaguar Health's stock reverse split before market open on Wednesday, September 8th 2021. The 1-3 reverse split was announced on Wednesday, September 8th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 8th 2021. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

What other stocks do shareholders of Jaguar Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biocept (BIOC), Sorrento Therapeutics (SRNE), Trevena (TRVN), Vaxart (VXRT), Purple Biotech (KTOV), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), Biopharmx (BPMX), Cara Therapeutics (CARA) and Conatus Pharmaceuticals (CNAT).

When did Jaguar Health IPO?

Jaguar Health (JAGX) raised $22 million in an initial public offering on Wednesday, May 13th 2015. The company issued 3,200,000 shares at $7.00 per share. Aegis Capital Corp served as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.

How do I buy shares of Jaguar Health?

Shares of JAGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:JAGX) was last updated on 4/23/2024 by Staff

From Our Partners